Contract announced for inhaled anthrax treatment

Officials with Elusys Therapeutics and Lonza announced this week that they have entered into an agreement for the commercial production of Anthim, an antibody for the treatment of inhaled anthrax.

Under terms of the contract, Lonza will provide scale-up, technology transfer and manufacturing of the therapeutic monoclonal antibody at one of its U.S. facilities.

James Porter, Elusys' vice president of development and manufacturing, said that he is looking forward to the partnership between the two companies.

“Elusys is pleased to extend its relationship with Lonza for the commercial production of Anthim, an anti-toxin that has been highly effective in treating anthrax infected animals,” Porter said. “Anthim has the potential to deliver significant therapeutic benefit to Americans infected with anthrax in a bioterrorism emergency and therefore, we believe that partnering with Lonza provides Elusys the manufacturing experience and large-scale capacity needed to ensure commercial quantities of Anthim long-term. As the world's leading contract manufacturer of monoclonal antibodies and recombinant proteins, Lonza has considerable experience in large-scale manufacturing and a well-established reputation with regulatory agencies for the production of licensed products.”

The manufacturing of Anthim was approved for full scale production by Lonza under a separate 2009 agreement.

Dr. Stephan Kutzer, head of custom manufacturing at Lonza, also expressed excitement about the new agreement.

“Working with the team at Elusys on such a novel new antibody therapy has been very rewarding,” Kutzer said. “We are excited about continuing our successful relationship and look forward to supporting Elusys in the launch and long-term commercial supply of Anthim.”